MURANO trial: 5-year updated results—Blood
The phase III GAIA/CLL13 trial: 15-month PFS and uMRD data—N Engl J Med
CLL information - Leukemia & Lymphoma Society
International Workshop on Chronic Lymphocytic Leukemia (iwCLL) - Blood
Updated January 25, 2023
CLL2-GIVEe Trial, preliminary results - Blood
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Living with Chronic Lymphocytic Leukemia (CLL)
CLL Guide
Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab